Welcome to our dedicated page for CDT Equity Inc, SEC filings (Ticker: CDTTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CDT Equity Inc,'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CDT Equity Inc,'s regulatory disclosures and financial reporting.
Amendment No. 3 to a Schedule 13D reports that Conduit Pharmaceuticals Inc. granted Dr. Andrew Regan 1,120,000 shares of common stock as director/officer compensation under the company’s Amended and Restated 2023 Stock Incentive Plan, valued at $0.6863 per share (closing Nasdaq price on September 18, 2025). The filing states 9,744,300 shares outstanding and discloses that Dr. Regan now beneficially owns 1,294,993 shares (approximately 13.3%) of the class, including shares held directly and through entities he controls. Corvus, Algo and Manoira ownership details are provided, and the Stock Incentive Plan is incorporated by reference as an exhibit.
On September 19, 2025, CDT Equity Inc. granted Dr. Andrew Regan 1,120,000 shares of common stock under its Amended and Restated 2023 Stock Incentive Plan as compensation for his services as a director and officer. The grant price reported reflects the closing price on September 18, 2025 at $0.6863 per share. After the grant, Dr. Regan directly beneficially owns 1,120,044 shares and also may be deemed to beneficially own additional shares held of record by Manoira Corporation, Corvus Capital Ltd., and Algo Holdings, Inc., entities connected to him by ownership and control.
James Bligh, CFO and Director of CDT Equity Inc. (CDT), was granted 480,000 shares of restricted common stock on 09/19/2025. The restricted shares were granted under the company's Amended and Restated 2023 Stock Incentive Plan and, according to the filing, vest immediately upon grant. The filing states the award had an approximate value of $329,424 based on the issuer's closing share price on 09/18/2025. After the reported transaction the Form 4 shows 480,024 shares beneficially owned by the reporting person in a direct ownership form. The filing is signed by James Bligh on 09/19/2025.
FAQ
What is the current stock price of CDT Equity Inc, (CDTTW)?
